TRCT
PHAT icon

Tower Research Capital (TRC)’s Phathom Pharmaceuticals PHAT Stock Holding History

Tower Research Capital (TRC)’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Sell
1,917
-24
-1% -$274 ﹤0.01% 3519
2026
Q1 		$21.6K Buy
1,941
+844
+77% +$10.7K ﹤0.01% 3432
2025
Q4 		$18.2K Sell
1,097
-465
-30% -$6.64K ﹤0.01% 3169
2025
Q3 		$18.4K Sell
1,562
-4,148
-73% -$42.8K ﹤0.01% 3387
2025
Q2 		$54.8K Buy
5,710
+2,102
+58% +$11.6K ﹤0.01% 2898
2025
Q1 		$22.6K Sell
3,608
-806
-18% -$4.89K ﹤0.01% 2844
2024
Q4 		$35.8K Buy
4,414
+27
+0.6% +$334 ﹤0.01% 2779
2024
Q3 		$79.3K Sell
4,387
-1,426
-25% -$19.9K ﹤0.01% 2418
2024
Q2 		$59.9K Buy
5,813
+5,233
+902% +$53.9K ﹤0.01% 2956
2024
Q1 		$6.16K Sell
580
-9,281
-94% -$78.8K ﹤0.01% 4422
2023
Q4 		$90K Buy
9,861
+550
+6% +$4.74K ﹤0.01% 2726
2023
Q3 		$96.6K Buy
9,311
+8,834
+1,852% +$121K ﹤0.01% 2007
2023
Q2 		$6.83K Sell
477
-1,228
-72% -$14.2K ﹤0.01% 4655
2023
Q1 		$12K Buy
1,705
+1,219
+251% +$10.7K ﹤0.01% 4112
2022
Q4 		$5K Sell
486
-3,965
-89% -$40.9K ﹤0.01% 4896
2022
Q3 		$49K Sell
4,451
-929
-17% -$8.85K ﹤0.01% 3174
2022
Q2 		$45K Buy
5,380
+1,684
+46% +$17.3K ﹤0.01% 2991
2022
Q1 		$51K Buy
3,696
+3,280
+788% +$53K ﹤0.01% 2715
2021
Q4 		$8K Sell
416
-190
-31% -$4.47K ﹤0.01% 4816
2021
Q3 		$19K Sell
606
-3,227
-84% -$107K ﹤0.01% 3769
2021
Q2 		$130K Buy
3,833
+2,517
+191% +$90.1K ﹤0.01% 2214
2021
Q1 		$49K Sell
1,316
-841
-39% -$35.2K ﹤0.01% 3150
2020
Q4 		$72K Sell
2,157
-9,055
-81% -$367K ﹤0.01% 2695
2020
Q3 		$411K Buy
11,212
+9,058
+421% +$314K ﹤0.01% 1901
2020
Q2 		$71K Buy
+2,154
New +$82.8K ﹤0.01% 2763

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Tower Research Capital (TRC)'s PHAT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Phathom Pharmaceuticals (PHAT) stake by 1.2% in Q2 2026, selling an estimated $274 and leaving 1,917 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3519.

Tower Research Capital (TRC) first reported a position in PHAT in Q2 2020 and has held it in 25 quarters since. The position peaked at $411K in Q3 2020. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Tower Research Capital (TRC) held 1,917 shares of Phathom Pharmaceuticals worth $20.8K as of Q2 2026.
  • Tower Research Capital (TRC) sold 24 Phathom Pharmaceuticals shares in Q2 2026, an estimated $274.
  • Phathom Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3519 holding.
  • Tower Research Capital (TRC) first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Phathom Pharmaceuticals position peaked at $411K in Q3 2020.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.